Sep 17,2019

Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe

Medtronic plc, the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Senseonics Announces the Completion of US Patient Enrollment in the PROMISE 180-Day Sensor Clinical Study

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the completion of patient enrollment in the Eversense PROMISE 180-day sensor Clinical Study.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 16,2019

Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes

Abbott and Omada Health announced they are partnering to integrate Abbott’s revolutionary FreeStyle Libre system, a CGM technology, with Omada Health’s pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes. Omada Health will offer the integrated solution to employers and health plans. People diagnosed with Type 2 diabetes who are eligible will be guided through a tailored experience that includes an online physician consultation, obtaining a prescription of Freestyle Libre and delivery of a welcome kit that includes the CGM system and a wireless scale.

COLLABORATION PARTNERSHIP

#connected device

#coaching

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 03,2019

Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona

Nemaura Medical, Inc., a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 08,2019

Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM

Dexcom, Inc. announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2019

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Abbott and Tandem Diabetes Care announced today that they intend to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading glucose sensing technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.

PRODUCT

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 24,2019

Senseonics Announces a Positive Coverage Decision for Eversense CGM From Humana

Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 12,2019

Medicare Establishes National Payment Rate for Eversense® CGM System

Senseonics announced today that the Centers for Medicare and Medicaid Services (CMS) finalized a national payment rate for Eversense that was recently published in the calendar year 2020 Physician Fee Schedule Final Rule. The Eversense CGM system will be the first CGM technology to be reimbursed through the Part B Medical Services benefit for Medicare beneficiaries and expands access to the latest innovation in continuous glucose monitoring.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 21,2019

Senseonics Publishes Positive Longitudinal Performance Over Multiple Sensor Insertions and Removal Cycles of the Eversense® CGM System

This real-world data of 945 adult users in the home-setting demonstrated that the performance of the sensor over four sensor cycles is stable and does not decrease over time. In addition, there was no degradation of patient glucose outcomes over the four sensor cycles.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 03,2019

Weekend server overload brings down Dexcom's CGM alert feature, raising alarms among parents

Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning. The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the service late Friday night, many users found themselves in a panic the next morning when they realized a major blood sugar event could have gone unnoticed.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM